Artificial Intelligence for Reconstruction of Echocardiography Studies

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Royal Wolverhampton Hospitals NHS Trust

About this trial

To investigate the clinical utility of both 3D and 2D artificial intelligence reconstruction echocardiography (V-echo and L-echo) assessment against conventional echocardiography and clinical cardiovascular magnetic resonance (CMR) imaging for the characterisation of cardiac function and detection of cardiotoxicity in patients receiving chemotherapy.

Diagnostic accuracy of V-echo and L-echo for quantification of cardiac chamber sizes and systolic function (left ventricular ejection fraction (LVEF) and strain analyses) versus conventional echocardiography (C-echo) and CMR; workflow measures including imaging temporal measures of image acquisition, registration and analysis versus conventional approaches; survey of markers of acceptability by patients and sonographers; cost effectiveness analysis of V-echo and L-echo versus conventional echocardiography; assessment of the relationship between 3D strain parameters derived from V-echo data, 2D strain parameters derived from L-echo and correlation with conventional markers of cardiac function, namely LVEF and global longitudinal strain.

Eligibility criteria

Qualifiers

Aged 18 years or older

Received potentially cardiotoxic chemotherapy

Participant requires echocardiography surveillance as standard current practice

Disqualifiers

Below the age of 18 years old

Inability to give informed consent

Implanted cardiac devices

Not having received cardiotoxic chemotherapy. Ineligible patients and patients not wishing to take part will be excluded, the reasons for this will be recorded and baseline CONSORT demographics noted including age, gender, ethnicity.

Trial design

Treatments tested in this trial

  • V-echo
  • L-echo

Treatment groups

120 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

The Royal Wolverhampton Hospitals NHS Trust

Lead sponsor

VentriPoint Diagnostics Ltd.

Collaborator